0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessWith over 2 years of follow-up, these clinically meaningful outcomes further support the use of SVd in patients who are lenalidomide-refractory, PI-naïve, bortezomib-naïve, or who received 1LOT (including a monoclonal antibody) and underscore the observed synergy between selinexor and bortezomib.
María‐Victoria Mateos, Monika Engelhardt, Xavier Leleu, Mercedes Gironella, Michèle Cavo, Meletios A Dimopoulos, Martina Bianco, G Merlo, Charles la Porte, Paul G. Richardson, Philippe Moreau (2024). Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the <scp>BOSTON</scp> trial. , 113(2), DOI: https://doi.org/10.1111/ejh.14223.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2024
Authors
11
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1111/ejh.14223
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
